Health & Biotech
PharmAust confirms cash boost for Phase 1 trials, with ATO approval for federal R&D refund
Health & Biotech
Osteopore expands further into Europe after delivering maiden sale to Spain
Health & Biotech
ASX Health Stocks: EU approval set to open up Wellfully’s knee patch to European markets
Health & Biotech
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
Health & Biotech
Medlab just axed another Q3 and now the Aussie world beater’s ready to deploy its vast global network
Health & Biotech
Medlab Clinical set to export first CBD product into the UK market
Health & Biotech
ASX Health Stocks: Chimeric and Proteomics are making moves to get ready for clinical trials
Health & Biotech
An ageing population is intensifying global health demand and EZZ’s life science brands are already top shelf solutions
Health & Biotech
ASX Health Stocks: ResApp skyrockets 25% after getting buyout offer from US giant Pfizer
Health & Biotech
Dr Boreham’s Crucible: Putting Microba under the microscope
Health & Biotech
Bring it on: PharmAust to start Phase 1 trial after first instalment lands from FightMND
Health & Biotech
ASX Health Stocks: Pro Medicus bags $32m deal, Kazia shows promise in child cancer drug
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.